Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Tolerability of Indacaterol Salts (Maleate, Xinafoate and Acetate) in Comparison to Placebo in Patients With Mild to Moderate Persistent Asthma
- First Posted Date
- 2008-02-27
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 98
- Registration Number
- NCT00624702
- Locations
- 🇨🇦
Novartis Investigator Site, Montreal, Quebec, Canada
Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2008-02-27
- Last Posted Date
- 2011-08-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 416
- Registration Number
- NCT00624286
- Locations
- 🇧🇪
Novartis Investigative Site, Lanaken, Belgium
🇳🇿Novartis Investigator Site, Tauranga, New Zealand
A Study of Efficacy of New Doses of Xolair to Protect From Allergen Challenge in Groups of Asthma Patients Defined by IgE Levels
- First Posted Date
- 2008-02-27
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 60
- Registration Number
- NCT00624832
- Locations
- 🇿🇦
Novartis Investigator Site, Durban, South Africa
A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)
- Conditions
- Alzheimer's Disease
- First Posted Date
- 2008-02-25
- Last Posted Date
- 2011-07-26
- Lead Sponsor
- Novartis
- Target Recruit Count
- 228
- Registration Number
- NCT00622713
- Locations
- 🇫🇷
Novartis Investigative Site, Rueil-Malmaison, France
Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)
- Conditions
- Parkinson's Disease Dementia
- Interventions
- First Posted Date
- 2008-02-25
- Last Posted Date
- 2011-11-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 583
- Registration Number
- NCT00623103
- Locations
- 🇺🇸
Collier Neurologic Specialists, Naples, Florida, United States
🇺🇸Neurological Associates, Meridian, Idaho, United States
🇺🇸Progressive Clinical Research, Bountiful, Utah, United States
The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2011-08-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 90
- Registration Number
- NCT00620022
- Locations
- 🇪🇸
Novartis Investigative Site, Madrid, Spain
🇪🇸Novartis Investigator Site, Zaragoza, Spain
🇪🇸Novartis Investigative site, Seville, Spain
Safety and Tolerability of Single and Multiple Doses of VAK694 in Healthy and Atopic Subjects
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2010-09-27
- Lead Sponsor
- Novartis
- Target Recruit Count
- 46
- Registration Number
- NCT00620230
- Locations
- 🇺🇸
Novartis Investigator Site, North Miami Beach, Florida, United States
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Rheumatoid Arthritis With Ongoing Treatment With Methotrexate
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2008-02-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 53
- Registration Number
- NCT00619905
- Locations
- 🇨🇭
Novartis Investigator Site, Geneva, Switzerland
Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 148
- Registration Number
- NCT00616811
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸Anasazi Internal Medicine, Phoenix, Arizona, United States
Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2011-08-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 96
- Registration Number
- NCT00615030
- Locations
- 🇪🇸
Novartis Investigative Site, Barcelona, Spain